Skip to main content
RCEL
NASDAQ Industrial Applications And Services

AVITA Q3 Revenue Up 53% to $26.1M; Guidance Raised, Going Concern Removed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$17.91
Mkt Cap
$484.933M
52W Low
$3.22
52W High
$16.9
52W Position info
456% above low
Off High info
at 52W high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

RCEL has more than doubled off its 52-week low of $3.22.

Summary

AVITA beat its own trajectory with 53% Q3 revenue growth to $26.1M, raised 2026 guidance to $92M-$94M, and removed the going-concern warning after drawing the final $10M credit tranche.


Key Events · Earnings and Guidance · RCEL

  • Q3 Revenue Jumps 53% to $26.1M

    Total revenue rose to $26.1M from $17.1M a year earlier, with RECELL U.S. revenue of $22.4M (about 20% sequential growth) and Cohealyx at $2.1M (about 21% sequential growth).

  • 2026 Guidance Raised to $92M-$94M

    Full-year revenue guidance moved up from $86M-$89M, implying $24.9M-$26.9M in Q4; the company reaffirmed cash flow breakeven in Q4 2026.

  • Going Concern Warning Removed

    Management concluded substantial doubt about the ability to continue as a going concern has been alleviated, and the Perceptive loan is now classified as a long-term liability.

  • Final $10M Credit Tranche Drawn

    Trailing twelve-month revenue of at least $85.0M satisfied the milestone; the $10.0M draw brings total borrowings under the Perceptive facility to $60 million.


Analysis · RCEL · Industrial Applications And Services

AVITA's Q3 revenue of $26.1M (up 53% year over year) came with an 84.0% gross margin and net cash use down to about $0.6M from $3.2M in Q2. The bigger change is the balance sheet: management concluded the substantial doubt about going concern has been alleviated, and the $10M Perceptive tranche was drawn after quarter-end, taking total borrowings to $60M and moving the loan to long-term. Full-year guidance rose to $92M-$94M from $86M-$89M, implying $24.9M-$26.9M in Q4, with cash flow breakeven still expected in Q4 2026. The $2.1M non-cash warrant revaluation expense is a mark-to-market driven by the higher share price, not new dilution or a cash outflow.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RCEL was trading at $17.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $484.9M. The 52-week trading range was $3.22 to $16.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RCEL - Latest Insights

RCEL
Nov 16, 2026, 8:08 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $16.20
Real-time Price: $15.95 info
Change: -$0.250 (-2%) info
Market Cap: $502.409M info
RCEL
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.70
Real-time Price: $15.95 info
Change: -$1.75 (-10%) info
Market Cap: $502.409M info
RCEL
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $16.65
Real-time Price: $15.95 info
Change: -$0.700 (-4%) info
Market Cap: $502.409M info
RCEL
Aug 18, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $15.95 info
Change: +$7.45 (+88%) info
Market Cap: $502.409M info
RCEL
Aug 11, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.20
Real-time Price: $15.95 info
Change: +$7.75 (+95%) info
Market Cap: $502.409M info